Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

breakingBAC

Financiado

Breaking resistance of pathogenic bacteria by chemical dysregulation

Antibiotic resistant bacteria are on the rise and could trigger the next global pandemic. For some pathogens no treatment options are left, leading to steadily increasing death tolls. The limited scope of bacterial targets, all es... ver más

31/08/2028

TUM

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

TECHNISCHE UNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-05

ERC-2022-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

TUM

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-15076 ANTIBIOTICOS INHIBIDORES DE NOVEDOSAS DIANAS TERAPEUTICAS: D... 204K€ Cerrado

CTQ2017-82222-R DESCUBRIMIENTO Y DESARROLLO DE NUEVOS COMPUESTOS QUIMICOS Y... 171K€ Cerrado

SAF2012-31919 ESTUDIO DE LA REGULACION GENICA BACTERIANA MEDIADA POR FACTO... 117K€ Cerrado

PID2020-119559RB-I00 MEDINAMICINA, UN NUEVO Y POTENTE INHIBIDOR DE LAS TRANSGLICO... 182K€ Cerrado

CTQ2014-60250-R DESARROLLO DE PROCESOS ENZIMATICOS PARA SU EMPLEO EN LA BIOP... 157K€ Cerrado

KpIspE Design and synthesis of novel inhibitors of the anti-infecti... 174K€ Cerrado

Duración del proyecto: 63 meses Fecha Inicio: 2023-05-05
Fecha Fin: 2028-08-31

Líder del proyecto

TECHNISCHE UNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Antibiotic resistant bacteria are on the rise and could trigger the next global pandemic. For some pathogens no treatment options are left, leading to steadily increasing death tolls. The limited scope of bacterial targets, all essential for growth, has favored resistance build-up whilst also being ineffective against non-growing persister cells. To overcome this threat, innovative concepts are required to effectively and sustainably kill bacteria via unprecedented mechanisms. My team and I tackle this challenge by deliberately going beyond established modes of action (MoA). To achieve this, we present breakingBAC: a three-tiered chemical strategy to dysregulate bacterial physiology. First, we will develop small molecule activators of crucial bacterial hydrolases to deregulate the degradation of proteins, leading to devastating physiological effects. Although enzyme stimulation has several advantages over inhibition, this concept is still in its infancy. We thus showcase principles of activator discovery and demonstrate their potency against diverse pathogens. Second, we recently discovered the complexation of free cellular heme by antibiotic isonitriles leading to a dysregulation of porphyrin biosynthesis and a corresponding induction of oxidative stress. Although these isonitriles are too large to access protein bound heme, we will tailor their structure to additionally target hemedependent enzymes of the stress response. The aim is to develop molecules bearing a dual MoA: a) stress induction and b) inhibition of stress response. Third, we will combine our learnings to create bifunctional compounds consisting of a hyperactivating protease recruiter linked to a bait which delivers the large class of essential heme-dependent enzymes for proteolysis. As these protein degraders are hyperactive, catalytic in nature, and specific for bacterial proteases, we anticipate potent antibiotic effects combined with low resistance frequencies and lack of human toxicity.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores